严重充血性心力衰竭中的乳清酸镁（MACH）

Magnesium orotate in severe congestive heart failure (MACH).

作者信息

Stepura O B, Martynow A I

机构信息

Russian County Moscow University of Medicine, Moscow, Russia.

出版信息

Int J Cardiol. 2009 May 1;134(1):145-7. doi: 10.1016/j.ijcard.2009.01.047.

DOI:10.1016/j.ijcard.2009.01.047

PMID:19367681

Abstract

BACKGROUND

Aim of this study was to evaluate adjuvant magnesium orotate on mortality and clinical symptoms in patients with severe heart failure under optimal cardiovascular medication.

METHODS

In a monocentric, controlled, double-blind study, 79 patients with severe congestive heart failure (NYHA IV) under optimal medical cardiovascular treatment were randomised to receive either magnesium orotate (6000 mg for 1 month, 3000 mg for about 11 months, n = 40) or placebo (n = 39). Both groups were comparable in demographic data, duration of heart failure and pre- and concomitant treatment.

RESULTS

After mean treatment duration of 1 year (magnesium orotate: 364.1 +/- 14.7 days, placebo: 361.2 +/- 12.7 days) the survival rate was 75.7% compared to 51.6% under placebo (p < 0.05). Clinical symptoms improved in 38.5% of patients under magnesium orotate, whereas they deteriorated in 56.3% of patients under placebo (p < 0.001).

CONCLUSION

Magnesium orotate may be used as adjuvant therapy in patients on optimal treatment for severe congestive heart failure, increasing survival rate and improving clinical symptoms and patient's quality of life.

摘要

背景

本研究旨在评估在接受最佳心血管药物治疗的重度心力衰竭患者中，辅助使用乳清酸镁对死亡率和临床症状的影响。

方法

在一项单中心、对照、双盲研究中，79例接受最佳心血管治疗的重度充血性心力衰竭（纽约心脏协会IV级）患者被随机分为两组，分别接受乳清酸镁（6000毫克，为期1个月；3000毫克，为期约11个月，n = 40）或安慰剂（n = 39）治疗。两组在人口统计学数据、心力衰竭持续时间以及前期和伴随治疗方面具有可比性。